When you stop taking Orilissa (elagolix), your body begins reversing most of the drug’s effects quickly. Estrogen levels return to normal within 24 to 48 hours after your last dose, which means the hormonal suppression that reduced your endometriosis pain wears off fast. Most changes reverse within weeks to months, but some, particularly bone density loss, may not fully recover.
Estrogen Rebounds Within Days
Orilissa works by partially blocking the signal that tells your ovaries to produce estrogen. Once you stop taking it, that signal resumes almost immediately. Your estrogen levels climb back to their pre-treatment baseline within one to two days. This rapid rebound is the reason most other changes, both the benefits and the side effects, begin shifting soon after your last pill.
Because estrogen drives endometriosis tissue growth and inflammation, the pain relief you experienced on Orilissa will fade as your hormone levels normalize. For many women, this means pelvic pain, painful periods, and pain during sex gradually return over the following weeks.
When Your Period Comes Back
Most women get their period back relatively quickly. In clinical trials, about 60% of women had a menstrual period within one month of stopping Orilissa. By six months, roughly 95% had resumed menstruating. If you were on the higher dose (200 mg twice daily), your cycle may have been more suppressed during treatment, but the timeline for return is similar.
Your first few cycles may be irregular. It can take a couple of months for your body to settle into a predictable pattern again, which is normal after any medication that suppresses ovarian activity.
Fertility After Stopping
Orilissa does not cause long-term infertility. Because ovulation can resume very quickly once estrogen rebounds, pregnancy is possible almost immediately. The FDA labeling advises using non-hormonal contraception (like condoms) during treatment and for 28 days after your last dose if you’re not trying to conceive. That 28-day window exists to clear the drug from your system and allow a normal hormonal cycle to establish before a potential pregnancy.
If you are hoping to conceive, the rapid hormonal recovery is good news. There is no recommended waiting period beyond that initial 28 days. Many reproductive specialists actually use short courses of hormonal suppression as part of fertility planning for endometriosis patients, timing surgery or IVF cycles for the period right after stopping medication.
Bone Density May Not Fully Recover
This is the most important long-term concern. Orilissa causes bone mineral density loss during treatment because lower estrogen levels reduce the body’s ability to maintain strong bones. The FDA’s risk assessment noted that this bone loss “may not be completely reversible” and that it increases with longer treatment duration. This is why Orilissa has strict time limits: no more than 24 months on the lower dose (150 mg once daily) and no more than 6 months on the higher dose (200 mg twice daily).
After stopping, some bone density does recover as estrogen returns, but the FDA’s clinical reviewers found a “lack of full recovery” in the data. The concern grows if you’ve used multiple hormonal suppression therapies over your lifetime, since bone loss from each course can accumulate. Women who are already at risk for osteoporosis, whether from family history, low body weight, or other factors, should be especially aware of this effect. If you took Orilissa for the full allowed duration, your doctor may recommend a bone density scan to check where you stand.
Cholesterol and Lipid Changes
During treatment, Orilissa causes dose-dependent increases in total cholesterol, LDL (“bad”) cholesterol, and triglycerides. These changes typically appear within the first one to two months and remain stable for as long as you take the drug. While the FDA labeling doesn’t provide a specific reversal timeline after stopping, the general expectation is that lipid levels improve as estrogen normalizes, since estrogen has a well-established protective effect on cholesterol metabolism. If you had lipid increases flagged during treatment, a follow-up blood test a few months after stopping can confirm whether your levels have normalized.
Mood and Emotional Side Effects
Orilissa carries a warning about mood changes, including depression, irritability, and in rare cases, suicidal thoughts. These side effects are linked to the low-estrogen state the drug creates. Once estrogen returns to baseline within a couple of days, the hormonal trigger for these mood changes is removed. Most women notice emotional side effects lifting within the first few weeks after stopping.
That said, hormonal fluctuations during the transition period can temporarily feel unsettling. Your body is readjusting, and the return of endometriosis pain on top of hormonal shifts can affect your emotional state. If you experienced significant mood symptoms during treatment, it’s worth paying attention to how you feel in the weeks after stopping and letting your doctor know if symptoms linger beyond a month or two.
Hot Flashes and Other Side Effects
The most common side effects of Orilissa, hot flashes, night sweats, headaches, and difficulty sleeping, are all driven by low estrogen. They resolve as hormone levels rebound. Most women find that hot flashes disappear within the first week or two. Headaches and sleep disruption may take slightly longer to fully settle, particularly if your menstrual cycle takes a few months to regulate.
Joint pain and nausea, which some women experience on Orilissa, also tend to clear within a few weeks of the last dose. The drug itself has a short half-life of about four to six hours, so it’s essentially out of your system within a day.
Pain Returning After Treatment
For most women, the central disappointment of stopping Orilissa is that endometriosis pain comes back. The drug suppresses symptoms but does not cure the underlying disease. Endometrial implants remain in place, and once estrogen returns, they become active again. Some women notice pain returning within a few weeks; for others, it may take a cycle or two before symptoms reach their previous intensity.
This is a common inflection point for treatment decisions. Some women move to a different medication, others pursue surgical excision of endometrial tissue, and some cycle back onto Orilissa after a break (though cumulative bone density loss needs to be considered). The timing of pain return can actually be useful information for your care team, since it helps confirm how much of your pain is estrogen-driven versus related to other factors like adhesions or pelvic floor dysfunction.